# Lucentis (Ranibizumab) for Eales' Disease

> **NCT00384449** · PHASE2,PHASE3 · COMPLETED · sponsor: **Oregon Health and Science University** · enrollment: 1 (actual)

## Conditions studied

- Eales' Disease

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT00384449
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2019-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00384449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00384449, "Lucentis (Ranibizumab) for Eales' Disease". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00384449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*